| Identification | Back Directory | [Name]
6-broMo-2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one | [CAS]
1016636-76-2 | [Synonyms]
PALBOCI
Palbociclib Impurity I
Palbociclib Intermediate 3
6-broMo-2-chloro-8-cyclopentyl-5-
6-broMo-2-chloro-8-cyclopentyl-5-Methylpyrido[2
6-bromo-2-chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7-one
6-broMo-2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-on
6-BroMo-2-chloro-8-cyclopentyl-5-Methyl-8H-pyrido[2,3-d]pyriMidin-7-one
6-broMo-2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one
Pyrido[2,3-d]pyriMidin-7(8H)-one, 6-broMo-2-chloro-8-cyclopentyl-5-Methyl-
6-bromo-2-chloro-8-cyclopentyl-5-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one
6-broMo-2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one(1016636-76-2)
6-bromo-2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one(For Palbociclib) | [EINECS(EC#)]
1592732-453-0 | [Molecular Formula]
C13H13BrClN3O | [MDL Number]
MFCD13181208 | [MOL File]
1016636-76-2.mol | [Molecular Weight]
342.619 |
| Chemical Properties | Back Directory | [Melting point ]
190-192°C | [Boiling point ]
468.4±45.0 °C(Predicted) | [density ]
1.645±0.06 g/cm3(Predicted) | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
Chloroform (Slightly, Sonicated), DMSO (Slightly), Methanol (Slightly, Sonicated) | [form ]
Solid | [pka]
-0.61±0.20(Predicted) | [color ]
White | [InChI]
InChI=1S/C13H13BrClN3O/c1-7-9-6-16-13(15)17-11(9)18(12(19)10(7)14)8-4-2-3-5-8/h6,8H,2-5H2,1H3 | [InChIKey]
HJQCAEDIUJXGCQ-UHFFFAOYSA-N | [SMILES]
C1(Cl)=NC=C2C(C)=C(Br)C(=O)N(C3CCCC3)C2=N1 |
| Questions And Answer | Back Directory | [Use]
6-Bromo-2-chloro-8-cyclopentyl-5-methylpyrido-[2,3-d]pyrimidin-7(8H)-one is used to prepare pyridino[2,3-d]pyrimidin-7(8H)-one derivatives as CDK4 and/or CDK6 inhibitors useful in the treatment of diseases. |
| Hazard Information | Back Directory | [Uses]
6-Bromo-2-chloro-8-cyclopentyl-5-methylpyrido-[2,3-d]pyrimidin-7(8H)-one is used to prepare pyridino[2,3-d]pyrimidin-7(8H)-one derivatives as CDK4 and/or CDK6 inhibitors useful in the treatment of diseases. |
|
|